Skip to content
October 24, 2022

Pete Smith, Ph.D.

Dr. Pete Smith is an Entrepreneur Partner at MPM BioImpact. He is the CSO of ReNAgade Therapeutics, an MPM portfolio company.  Pete has over 30 years of industry experience and is a proven leader in early drug discovery and development having held key senior roles at Alnylam Pharmaceuticals, Moderna Therapeutics and Millennium Pharmaceuticals.

Prior to joining MPM BioImpact, Pete was Chief Early Development Officer at Alnylam Pharmaceuticals focusing on RNAi-based medicines in four therapeutic areas including genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system and ocular diseases.  Prior to Alnylam, Pete was SVP and head of R&D Non-Clinical at Moderna and served as co-head of R&D at Millennium where he worked for 13 years.  He has extensive experience in drug discovery and development across multiple therapeutic areas including oncology, inflammation, infectious Disease amongst others and technologies including new modalities such as mRNA and siRNA.  During his career, Pete has overseen the development of multiple therapeutics, such as Celebrex™, Inspra™, Velcade™, Entyvio™, Onpattro™, Givlarri™, Oxlumo™ and Vutrisiran.  Pete began his career with 17 years in industry at SmithKline, Merck, Searle/Monsanto and Pharmacia in roles of increasing responsibility.

Pete earned a Ph.D. in Pharmacology and Toxicology from the University of Arizona, and a B.S from Fairfield University.